ARC fusion protein SL-279252

{
  "id": "MLC-T-ONC-011219",
  "term": "ARC fusion protein SL-279252",
  "field": "Oncology and biomedicine",
  "definition": "An agonist redirected checkpoint (ARC) fusion protein consisting of the extracellular domains of human programmed cell death 1 (PD-1; PDCD1; CD279) and tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 ligand; OX40L; CD252), linked by a central Fc domain (PD1-Fc-OX40L), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, ARC fusion protein SL-279252 simultaneously binds to both tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40) and PD-1 expressed on T lymphocytes. Stimulation of OX40 may promote cytokine production and induce proliferation of memory and effector T lymphocytes against tumor cells, while PD-1 binding disrupts PD-1 signaling and may restore immune function through the activation of T cells. This may enhance the immune-mediated elimination of tumor cells more effectively than PD-1 blockade or OX40-agonism alone. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.",
  "synonyms": [
    "agonist redirected checkpoint fusion protein SL-279252",
    "PD1-Fc-OX40L ARC fusion protein"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/arc-fusion-protein-sl-279252/"
}